Babis Andreadis, MD
Professor
Medicine
School of Medicine

Awards

Show all (12) Hide

• Bay Area Man of the Year, Leukemia & Lymphoma Society, 2015
• Finalist for the 2013-2014 Distinction in Teaching Award, UCSF, 2014
• Marc A. Shuman Mentoring Award, Division of Hematology/Oncology, UCSF, 2013
• Hematology Teaching Award, Division of Hematology/Oncology, UCSF, 2012
• The Endocrine Society Medical Student Achievement Award, Columbia University, 1998
• Alpha Omega Alpha, A of New York, 1997
• Grove memorial Scholarship, Columbia University, 1996
• McGraw-Hill Publishers Award, Columbia University, 1995
• Nicholplus Interschool Fellowship, Columbia University, 1994
• Harry N. Holmes Prize of Excellence in Chemistry, Oberlin college, 1993
• Phi Beta Kappa, Z of Ohio, 1992
• Franklin F. Jewett Award, Oberlin College, 1991

Education & Training

Show all (5) Hide

• M.S.C.E. Pharmacogenetics University of Pennsylvania, Philadelphia, PA 2005
• Fellow Hematology/Oncology Hospital of the University of Pennsylvania 2004
• Resident Internal Medicine Columbia-Presbyterian Medical Center 2001
• MD Medicine College of Physicians & Surgeons, Columbia University, New York 1998
• BA Cum Laude, Biochemistry Oberlin College, Oberlin, OH 1993

Websites

Show all (2) Hide

• Profile at UCSF Cancer Center (cancer.ucsf.edu)
• Clinical Profile at UCSF Medical Center (ucsfhealth.org)

Publications (8)

Top publication keywords:
Germinal CenterSalvage TherapyHematopoietic Stem Cell TransplantationLymphoma, Large B-Cell, DiffuseNeoplasm Recurrence, LocalRetreatmentEtoposideAntigens, CD19Leukemia, Myeloid, AcuteProteomicsBendamustine HydrochlorideLymphoma, Non-HodgkinCytarabineTransplantation, AutologousAntineoplastic Combined Chemotherapy Protocols

• Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.
  Blood 2026 Wierda WG, Dorritie KA, Gauthier J, Nath R, Kipps TJ, Riedell PA, Eradat HA, Kenderian SS, Kharfan-Dabaja MA, Shah NN, Solomon SR, Stephens DM, Ermann DA, Arnason JE, Deol A, Feldman TA, Andreadis CB,…
• Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study.
  Blood neoplasia 2026 Timmerman J, Lavie D, Johnson NA, Avigdor A, Borchmann P, Andreadis C, Bazargan A, Gregory GP, Keane C, Tzoran I, Vucinic V, Zinzani PL, West RM, Pillai P, Marinello P, Herrera AF
• Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma.
  Leukemia & lymphoma 2025 Othman T, Lo MM, Andreadis CB, Damon LE, Ferng TT, Gaensler KML, Lee JC, Martin TG, Olin RL, Sayre PH, Smith CC, Logan AC
• Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma.
  American journal of hematology 2024 Thiruvengadam SK, Merryman R, Wang Y, Gaulin C, Bezerra E, Voorhees T, Seshadri MR, Falade A, Habib A, Ayers AA, Bailey M, Brown A, Bailey N, Patel K, Andreadis CB, Kittai AS, Jacobson C, Palmer J, …
• Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis.
  Blood cancer discovery 2021 Wang VE, Blaser BW, Patel RK, Behbehani GK, Rao AA, Durbin-Johnson B, Jiang T, Logan AC, Settles M, Mannis GN, Olin R, Damon LE, Martin TG, Sayre PH, Gaensler KM, McMahon E, Flanders M, Weinberg V, Ye…
• Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial.
  Clinical lymphoma, myeloma & leukemia 2020 Kambhampati S, Fakhri B, Ai WZ, Kaplan LD, Tuscano JM, Wieduwilt MJ, Sudhindra A, Cavallone E, Reiner J, Aoun C, Castillo M, Martinelli M, Ta T, Le D, Padilla M, Crawford E, Andreadis CB
• Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation.
  Clinical lymphoma, myeloma & leukemia 2020 Thiruvengadam SK, Hunter B, Varnavski A, Fakhri B, Kaplan L, Ai WZ, Pampaloni M, Huang CY, Martin T, Damon L, Andreadis CB
• Serial comprehensive geriatric and quality of life assessments in adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation.
  Journal of geriatric oncology 2020 Nawas MT, Sheng Y, Huang CY, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Olin RL